Myeloma
The latest news, research, and perspectives in multiple myeloma. Multiple myeloma is characterized by the proliferation of malignant plasma cells that accumulate in the bone marrow and produce abnormal immunoglobulin. Read more about the pathophysiology, diagnosis, staging, and treatment of myeloma.
Advertisement
Next-gen BCL-2 inhibitors show promise in RRMM as venetoclax struggles with OS in phase 3 BELLINI study.
Experts explore inflammation, immune escape, and diverging approaches in managing precursor myeloma.
Gaps in coordination and collaboration between primary care and oncology may impact long-term survival outcomes for patients.
Experts discuss quadruplet therapy, MRD, and evolving transplant decisions in newly diagnosed multiple myeloma.
Experts debate immune escape, inflammation, and early intervention in relapsed/refractory multiple myeloma.
Linvoseltamab earns FDA nod for RRMM with 70% ORR, monthly dosing, and lower CRS than other bispecifics.
Advertisement
Blood Cancers Today editors Krina Patel and Rahul Banerjee reflect on paradigm-shifting myeloma research from ASCO.
A U.S. claims database study revealed how clinicians are administering elranatamab therapy in the real-world setting.
Talquetamab plus teclistamab yields high responses in patients with relapsed/refractory myeloma and extramedullary disease.
Dr. Susan Bal unpacks the promise of GPRC5D CAR T therapy in relapsed/refractory multiple myeloma.
Elotuzumab added to KRd shows a favorable trend in 3-year PFS for NDMM patients, EHA 2025 study finds.
Talquetamab remains effective in tough-to-treat myeloma—even when patients develop immune responses.
The ratio of T cells to neutrophils at the time of leukapheresis was associated with better outcomes, Dr. Voorhees explained.
Isatuximab added to bortezomib, lenalidomide, and dexamethasone showed a significant PFS benefit in myeloma.
Elranatamab shows durable responses and manageable safety in heavily pretreated US patients with myeloma.
Blood clot risk tools may fall short for myeloma patients—study shows aspirin alone might not be enough.
Belantamab may return for RRMM after DREAMM trials show benefit, despite ongoing concerns about eye toxicity.
The three-arm study enrolled patients with disease refractory to prior carfilzomib, daratumumab, or pomalidomide therapy.
At 5 years, 33% of patients with myeloma receiving cilta-cel in the CARTITUDE-1 trial are alive and disease free.
The median progression-free survival was 33.2 months in the BVd arm, compared with 11.1 months in the DVd arm.
630 Madison Ave.
Manalapan, NJ 07726
© 2025 Mashup Media, LLC, a Formedics Property. All Rights Reserved.